Ganciclovir
别名: RS-21592, BW-759, 2'-Nor-2'-deoxyguanosine 中文名称：更昔洛韦,丙氧鸟苷
Ganciclovir是一种抗病毒药，作用于猫科动物1型疱疹病毒，无细胞试验中IC50为5.2 μM。
Ganciclovir Chemical Structure
CAS: 82410-32-0
产品质控
批次：
纯度：
99.96%
99.96
Ganciclovir相关产品
| 相关靶点 | HCMV | 点击展开 |
|---|---|---|
| 相关产品 | Bisindolylmaleimide IV | 点击展开 |
| 相关化合物库 | 抗感染化合物库 抗生素化合物库 抗病毒化合物库 抗寄生虫药物库 肠道微生物代谢物库 | 点击展开 |
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HFF | Antiviral assay | 5 uM | Antiviral activity against HCMV Towne infected in human HFF cells assessed as reduction in viral DNA yields in the supernatant at 5 uM treated with compound following viral infection at MOI of 0.1 PFU/cell by US17 real time PCR analysis | 32191456 | |
| HFF | Antiviral assay | 5 uM | Antiviral activity against HCMV Towne infected in human HFF cells assessed as reduction in viral DNA replication at 5 uM treated with compound following viral infection at MOI of 0.1 PFU/cell by US17 real time PCR analysis | 32191456 | |
| Vero | Function assay | 10 uM | Inhibition of UL42 gene transcription in HSV-1 infected in African green monkey Vero cells at 10 uM by qRT-PCR analysis | 31503476 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50=0.01μM. | 30286952 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50=0.01μM. | 30286952 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50=0.019μM. | 29550734 | |
| HEL | Antiviral assay | 4 days | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50=0.02μM. | 22459876 | |
| Vero | Antiviral assay | 72 hrs | Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis, EC50=0.025μM. | 31503476 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50=0.03μM. | 20034711 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50=0.03μM. | 20034711 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50=0.03μM. | 20034711 | |
| HEL | Antiviral assay | 4 days | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50=0.03μM. | 21696963 | |
| HEL | Antiviral assay | 4 days | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50=0.03μM. | 21696963 | |
| HEL | Antiviral assay | 4 days | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50=0.03μM. | 22459876 | |
| HFF | Antiviral assay | 1 hr | Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50=0.04μM. | 21376429 | |
| Vero | Antiviral assay | 36 hrs | Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay, EC50=0.04μM. | 32191456 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50=0.045μM. | 29550734 | |
| human | Antiviral assay | 7 days | Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50=0.05μM. | 21128666 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50=0.051μM. | 29670705 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50=0.057μM. | 29670705 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay, EC50=0.07μM. | ChEMBL | |
| HELF | Antiviral assay | 7 days | Antiviral activity against Herpes simplex virus 1 KOS infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis, EC50=0.07μM. | 31586832 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50=0.08μM. | 21128666 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay, EC50=0.08μM. | ChEMBL | |
| HEL | Antiviral assay | 3 days | Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay, EC50=0.08μM. | ChEMBL | |
| HEL | Antiviral assay | 3 days | Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay, EC50=0.09μM. | ChEMBL | |
| HFF | Antiviral assay | 10 days | Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay, IC50=0.14μM. | 21812420 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50=0.2μM. | 30286952 | |
| HELF | Antiviral assay | 7 days | Antiviral activity against Herpes simplex virus 2 G infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis, EC50=0.3μM. | 31586832 | |
| HS27 | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay, EC50=0.32μM. | 20047911 | |
| Vero | Antiviral assay | 36 hrs | Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay, EC50=0.58μM. | 32191456 | |
| HEL | Antiviral assay | 5 days | Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50=0.59μM. | 19339082 | |
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=0.7μM. | 17438061 | |
| HFF | Antiviral assay | 8 to 10 days | Antiviral activity against HCMV TB40 infected in human HFF cells assessed as reduction in plaque formation treated with compound following viral infection and incubated for 8 to 10 days by crystal violet staining based assay, EC50=0.72μM. | 32191456 | |
| fibroblast cells | Antiviral assay | 1 hour | Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50=0.8μM. | 16134946 | |
| fibroblast cells | Antiviral assay | 1 hour | Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50=0.8μM. | 16134946 | |
| HEL | Antiviral assay | 4 days | Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50=0.8μM. | 21696963 | |
| HELF | Antiviral assay | 7 days | Antiviral activity against Herpes simplex virus 1 TK-KOS-ACV infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis, EC50=0.8μM. | 31586832 | |
| Vero | Antiviral assay | 3 days | Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay, EC50=0.9μM. | 26460883 | |
| MEF | Antiviral assay | 3 days | Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay, EC50=0.96μM. | 32191456 | |
| HFF | Antiviral assay | 5 days | Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay, IC50=1μM. | 17329103 | |
| HEL | Antiviral assay | 5 days | Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days, EC50=1.1μM. | 19339082 | |
| CRFK | Antiviral assay | 3 days | Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as inhibition of virus-induced cytopathicity after 3 days, EC50=1.2μM. | 23047229 | |
| HEL | Antiviral assay | 7days | Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days, EC50=1.3μM. | 17539622 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=1.3μM. | 17961851 | |
| Vero | Antiviral assay | 3 days | Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay, EC50=1.4μM. | 26460883 | |
| MRC5 | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay, EC50=1.65μM. | 20047911 | |
| HEL | Antiviral assay | 4 days | Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50=1.65μM. | 22459876 | |
| HEL | Antiviral assay | 4 days | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50=1.65μM. | 22459876 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=2μM. | 19226140 | |
| HFF | Antiviral assay | 8 days | Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay, IC50=2.1μM. | 22607883 | |
| HFF | Antiviral assay | 8 to 10 days | Antiviral activity against HCMV Towne infected in human HFF cells assessed as reduction in plaque formation treated with compound following viral infection and incubated for 8 to 10 days by crystal violet staining based assay, EC50=2.1μM. | 32191456 | |
| Vero | Antiviral assay | 3 days | Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay, EC50=2.14μM. | 26460883 | |
| HEL | Antiviral assay | 5 days | Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days, EC50=2.3μM. | 17622128 | |
| HELF | Antiviral assay | 7 days | Antiviral activity against Cytomegalovirus Davis infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis, EC50=2.3μM. | 31586832 | |
| HEL299 | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay, EC50=2.39μM. | 20047911 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50=2.5μM. | 19339082 | |
| HEL | Antiviral assay | 5 days | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50=2.5μM. | 19339082 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against CMV Davis in human HEL cells after 7 days, EC50=2.6μM. | 17672445 | |
| hhTERT-BJ1 | Antiviral assay | 2 days | Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days, EC50=3μM. | 18458124 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50=3μM. | 21128666 | |
| HFF | Antiviral assay | 10 days | Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days, IC50=3μM. | 21641218 | |
| HELF | Antiviral assay | 7 days | Antiviral activity against Cytomegalovirus AD169 infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis, EC50=3.15μM. | 31586832 | |
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50=3.31μM. | 29670705 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=3.6μM. | 19226140 | |
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50=3.91μM. | 29550734 | |
| CRFK | Antiviral assay | 4 days | Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay, EC50=4.1μM. | 22459876 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50=4.72μM. | 26291038 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days, EC50=4.8μM. | 17539622 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=4.8μM. | 17961851 | |
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50=4.83μM. | 29550734 | |
| HFF | Antiviral assay | 5 to 7 days | Antiviral activity against HCMV infected HFF cells after 5 to 7 days by viral yield assay, EC99.9=5μM. | 17329103 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50=5.1μM. | 17622128 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50=5.2μM. | 21128666 | |
| AKATA | Antiviral assay | 48 hrs | Antiviral activity against EBV infected in human AKATA cells assessed as reduction in IgG-induced lytic virus replication measured at 48 hrs post-lytic induction by qRT-PCR analysis, EC50=5.2μM. | 32191456 | |
| NIH 3T3 | Antiviral assay | 4 to 5 days | Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay, EC50=5.7μM. | 18458124 | |
| RG2TK+ | Cytotoxicity assay | 72 hrs | Cytotoxicity against HSV1-tk gene overexpressing RG2TK+ cells after 72 hrs by MTT assay, CC50=5.86μM. | 18800764 | |
| HEL | Antiviral assay | 3 days | Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay, EC50=6μM. | ChEMBL | |
| HEL | Antiviral assay | 7 days | Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50=6.12μM. | 26291038 | |
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50=6.46μM. | 29550734 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against CMV AD169 in human HEL cells after 7 days, EC50=6.5μM. | 17672445 | |
| CRFK | Antiviral assay | 3 days | Antiviral activity against Felid herpesvirus 1 infected cat CRFK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay, EC50=7.3μM. | ChEMBL | |
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50=7.41μM. | 29670705 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50=8.7μM. | 17622128 | |
| Vero | Antiviral assay | 3 days | Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay, EC50=11.1μM. | 26460883 | |
| HEL | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50=12.6μM. | 19339082 | |
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=14.5μM. | 17438061 | |
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=19.2μM. | 17438061 | |
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=23.5μM. | 17438061 | |
| HFF | Antiviral assay | 8 to 10 days | Antiviral activity against GCV-resistant HCMV Towne infected in human HFF cells assessed as reduction in plaque formation treated with compound following viral infection and incubated for 8 to 10 days by crystal violet staining based assay, EC50=29.7μM. | 32191456 | |
| bone marrow cells | Cytotoxicity assay | 15 days | Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days, CC50=30μM. | 17329103 | |
| HFF | Antiviral assay | 6 hrs | Antiviral activity against pp28-luciferase expressing HCMV Towne infected in human HFF cells assessed as reduction in viral replication treated with compound immediately after viral infection at MOI of 1 PFU/cell followed by compound washout after 6 hrs a | 32191456 | |
| HEL | Antiviral assay | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.013μM. | 23099097 | ||
| HEL | Antiviral assay | Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50=0.01μM. | 23795238 | ||
| HEL | Antiviral assay | Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50=0.01μM. | 23795238 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.01μM. | 21232828 | ||
| HEL | Antiviral assay | Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC=0.0064μM. | 17672445 | ||
| OST TK- cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK, IC50=0.0019μM. | 17181158 | ||
| E6SM cell lines | Function assay | Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines, EC50=1.2 nM | 11495586 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.015μM. | 23099097 | ||
| OST TK- cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50=0.018μM. | 17181158 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells, EC50=0.019μM. | 17181162 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50=0.02μM. | 19281225 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=0.02μM. | 26001344 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.02μM. | 29880251 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.02μM. | 29880251 | ||
| HEL | Antiviral assay | Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50=0.027μM. | 21565516 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay, EC50=0.027μM. | 22858222 | ||
| HEL | Antiviral assay | Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay, EC50=0.029μM. | 22858222 | ||
| HEL | Antiviral assay | Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50=0.03μM. | 21565516 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=0.03μM. | 23811093 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=0.03μM. | 23811093 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=0.03μM. | 26001344 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation, EC50=0.03μM. | 27639368 | ||
| HELF | Antiviral assay | Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50=0.03μM. | 30098481 | ||
| HELF | Antiviral assay | Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50=0.03μM. | 30098481 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.03μM. | 28829913 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.03μM. | 28757102 | ||
| HEL | Antiviral assay | Antiviral activity against HSV2 in HEL cells, EC50=0.032μM. | 17181162 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC=0.032μM. | 17672445 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50=0.032μM. | 27750154 | ||
| OST TK- cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50=0.033μM. | 17181158 | ||
| fibroblast cells | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.04μM. | 19397271 | ||
| HEL | Antiviral assay | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.04μM. | 21232828 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.04μM. | 28829913 | ||
| HEL | Antiviral assay | Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.04μM. | 28757102 | ||
| OST TK- cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50=0.041μM. | 17181158 | ||
| OST TK- cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50=0.05μM. | 17181158 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50=0.055μM. | 27750154 | ||
| HEL | Function assay | Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50=0.06μM. | 14643328 | ||
| Hel | Function assay | Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells, EC50=0.06μM. | 15658858 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells, EC50=0.06μM. | 16392791 | ||
| HEL | Antiviral assay | Antiviral activity against HSV2 G in HEL cells, EC50=0.06μM. | 16392791 | ||
| HEL | Antiviral assay | Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis, EC50=0.07μM. | 30738653 | ||
| OST TK- cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50=0.081μM. | 17181158 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation, EC50=0.09μM. | 27639368 | ||
| E6SM | Antiviral assay | Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells, MIC=0.096μM. | 17092728 | ||
| E6SM | Antiviral assay | Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells, MIC=0.096μM. | 17092728 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.1μM. | 21232828 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.1μM. | 28757102 | ||
| OST TK- cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50=0.11μM. | 17181158 | ||
| HFF | Function assay | Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay, EC50=0.15μM. | 17004726 | ||
| MCA-TK | Cytotoxicity assay | Cytotoxicity against MCA-TK cells, IC50=0.15μM. | 17960926 | ||
| vero | Antiviral assay | Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain, ID50=0.2μM. | 3871860 | ||
| Vero | Antiviral assay | In vitro antiviral activity was measured against HSV-1(F) in Vero cells, ID50=0.2μM. | 3009811 | ||
| Vero | Antiviral assay | Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells, ID50=0.2μM. | 3016263 | ||
| HEL | Antiviral assay | Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity, EC50=0.2μM. | 19281225 | ||
| fibroblast cells | Function assay | Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%, EC50=0.23μM. | 11585457 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD169 infected in HEL cells, EC50=0.25μM. | 27128178 | ||
| vero | Antiviral assay | In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture, ID50=0.3μM. | 2993615 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation, EC50=0.38μM. | 23911856 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells, EC50=0.4μM. | 27128178 | ||
| HEL | Antiviral assay | Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis, EC50=0.4μM. | 30738653 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells, EC50=0.48μM. | 17181162 | ||
| HFF | Function assay | Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells, EC50=0.5μM. | 8394933 | ||
| HEL | Function assay | Inhibition of human CMV DNA synthesis in CMV-infected HEL cells, IC50=0.5μM. | 7752205 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=0.5μM. | 26001344 | ||
| HELF | Antiviral assay | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50=0.5μM. | 30098481 | ||
| HEL | Antiviral assay | Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.66μM. | 19226140 | ||
| HEL | Antiviral assay | Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.69μM. | 19226140 | ||
| HEL | Antiviral assay | Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.7μM. | 19226140 | ||
| E6SM | Antiviral assay | Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells, MIC=0.8μM. | 17092728 | ||
| HEL | Antiviral assay | Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.8μM. | 29880251 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis, EC50=0.8μM. | 30738653 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50=0.9μM. | 23911856 | ||
| CRFK | Antiviral assay | Antiviral activity against Feline Herpes virus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay, EC50=0.9μM. | 23911856 | ||
| MRC5 | Antiviral assay | Antiviral activity against HCMV in MRC5 cells by plaque reduction assay, IC50=0.91μM. | 17239594 | ||
| HEL | Antiviral assay | Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50=1μM. | 23795238 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50=1.1μM. | 17709468 | ||
| CRFK | Antiviral assay | Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay, EC50=1.15μM. | 22858222 | ||
| HEL | Antiviral assay | Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=1.2μM. | 19226140 | ||
| fibroblast cells | Antiviral assay | Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay, EC50=1.2μM. | 19397271 | ||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay, IC50=1.2μM. | 15509176 | ||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50=1.2μM. | 15509176 | ||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50=1.2μM. | 15509176 | ||
| FRCK | Antiviral assay | Antiviral activity against Feline herpesvirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity, EC50=1.2μM. | 19281225 | ||
| vero | Antiviral assay | In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells, ID50=1.3μM. | 2993615 | ||
| fibroblast cells | Antiviral assay | Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO, IC50=1.3μM. | 16134946 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay, IC50=1.3μM. | 17043128 | ||
| HFF | Antiviral assay | Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay, IC50=1.3μM. | 17434304 | ||
| HFF | Antiviral assay | Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay, IC50=1.3μM. | 20167488 | ||
| HFF | Function assay | Inhibition of HCMV DNA polymerase infected in HFF cells, IC50=1.3μM. | 20403696 | ||
| MRC5 | Function assay | Inhibitory concentration against Davis strain of HCMV in MRC5 cells, IC50=1.4μM. | 11454465 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50=1.4μM. | 17043128 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay, IC50=1.4μM. | 17043128 | ||
| MRC5 | Function assay | Inhibitory concentration against Towne strain of HCMV in MRC5 cells, IC50=1.5μM. | 11454465 | ||
| CCL81 | Antiviral assay | Antiviral activity against HSV1 in CCL81 cells, EC50=1.5μM. | 17188402 | ||
| CCL81 | Antiviral assay | Antiviral activity against HSV2 in CCL81 cells, EC50=1.5μM. | 17188402 | ||
| MRC5 | Function assay | Inhibitory concentration against 2599R strain of HCMV in MRC5 cells, IC50=1.6μM. | 11454465 | ||
| Vero | Antiviral assay | In vitro antiviral activity was measured against HSV-2(G) in Vero cells, ID50=1.6μM. | 3009811 | ||
| HFF | Function assay | In vitro reduction in yield of Towne strain of HCMV in HFF (human fibroblast) cells, IC90=1.6μM. | 9057865 | ||
| HFF | Function assay | Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by yield reduction assay, IC90=1.6μM. | 9438017 | ||
| HFF | Function assay | Compound was tested for antiviral activity against Towne strain of HCMV in a yield reduction assay using HFF cells, IC90=1.6μM. | 10882374 | ||
| HFF | Function assay | Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by yield reduction assay using HFF cells, IC90=1.6μM. | 10882375 | ||
| HFF | Antiviral assay | Antiviral activity against towne strain HCMV was determined by yield reduction assay in duplicate wells using HFF cells, IC90=1.6μM. | 10882370 | ||
| HFF | Antiviral assay | Antiviral activity against HCMV was determined by yield reduction assay using HFF cells, IC90=1.6μM. | 10882372 | ||
| HFF | Function assay | Inhibition of HCMV towne replication in HFF cells by plaque reduction assay, EC50=1.8μM. | 17004726 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV AD169 in HFF cells by PRA, IC50=1.9μM. | 17043128 | ||
| HFF | Function assay | Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay, EC50=2.1μM. | 15615545 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation, EC50=2.1μM. | 27639368 | ||
| HFF | Function assay | Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay, EC50=2.2μM. | 15615545 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=2.29μM. | 29880251 | ||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50=2.5μM. | 15509176 | ||
| HFF | Antiviral assay | Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay, EC50=2.5μM. | 18082410 | ||
| HFF | Function assay | Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay, IC50=2.6μM. | 9438017 | ||
| HEL | Antiviral assay | Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=2.6μM. | 19226140 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay, EC50=2.6μM. | 17709468 | ||
| CRFK | Antiviral assay | Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay, EC50=2.6μM. | 20034711 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay, EC50=2.7μM. | 17709468 | ||
| HEL | Antiviral assay | Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation, EC50=2.75μM. | 17518459 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=2.96μM. | 28757102 | ||
| BSC-1 | Antiviral assay | Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50=3μM. | 2913300 | ||
| MRC5 | Function assay | Inhibitory concentration against AD169 strain of HCMV in MRC5 cells, IC50=3μM. | 11454465 | ||
| HFF | Antiviral assay | Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay, IC50=3μM. | 17161946 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation, EC50=3.1μM. | 23911856 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation, EC50=3.1μM. | 27639368 | ||
| HFF | Antiviral assay | Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay, IC50=3.22μM. | 19010684 | ||
| HFF | Function assay | Compound was tested for antiviral activity against wild-type AD169 strain of HCMV in yield reduction assay using HFF cells, IC90=3.3μM. | 10882374 | ||
| MEF | Function assay | Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay, IC50=3.4μM. | 9438017 | ||
| BSC-1 | Antiviral assay | Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells, IC50=3.5μM. | 10882370 | ||
| BSC-1 | Function assay | ELISA assay was performed using BSC-1 cells to determine activity against HSV-1, IC50=3.5μM. | 10882372 | ||
| BSC-1 | Antiviral assay | In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells, IC50=3.5μM. | 9057865 | ||
| HEL | Antiviral assay | Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=3.5μM. | 19226140 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay, EC50=3.5μM. | 17709468 | ||
| BSC-1 | Function assay | Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50=3.5μM. | 15509174 | ||
| BSC-1 | Function assay | Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50=3.5μM. | 15509175 | ||
| BSC-1 | Function assay | Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50=3.5μM. | 15509176 | ||
| HFF | Function assay | Compound was tested for antiviral activity against 2916 AD169 strain of HCMV in yield reduction assay using HFF cells, IC90=3.6μM. | 10882374 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay, EC50=3.9μM. | 17709468 | ||
| MRC-5 | Antiherpesvirus assay | In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain), IC50=4μM. | 1323678 | ||
| HEL | Antiviral assay | Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=4μM. | 19226140 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=4μM. | 23099097 | ||
| HEL | Antiviral assay | Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=4μM. | 23811093 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50=4μM. | 27750154 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect, EC50=4.05μM. | 29407990 | ||
| HFF | Function assay | Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells, IC50=4.1μM. | 10882374 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2291 in HFF cells by PRA, IC50=4.1μM. | 17043128 | ||
| CRFK | Antiviral assay | Antiviral activity against feline herpesvirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay, EC50=4.1μM. | 23811093 | ||
| HEL | Antiviral assay | Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=4.3μM. | 19226140 | ||
| HEL | Antiviral assay | Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=4.3μM. | 28829913 | ||
| HFF | Function assay | Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells, IC50=4.5μM. | 10882374 | ||
| MRC5 | Antiviral assay | Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50=4.9μM. | 17043128 | ||
| MRC5 | Antiviral assay | In vitro antiviral activity was measured against HCMV(AD-169) in MRC5 cells, ID50=5μM. | 3009811 | ||
| H-1 | Function assay | Effective concentration required to inhibit Epstein-barr virus replication in H-1 cells in DNA hybridization assay, EC50=5μM. | 15634003 | ||
| H1 | Function assay | Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50=5μM. | 17004726 | ||
| H1 | Function assay | Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50=5μM. | 15615545 | ||
| CEM | Cytotoxicity assay | Cytotoxicity against CEM cells, CC50=5μM. | 15615545 | ||
| MRC5 | Antiviral assay | Antiviral activity against Human CMV T2296 in MRC5 cells by PRA, IC50=5.4μM. | 17043128 | ||
| fibroblast cells | Antiviral assay | Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay, EC50=5.5μM. | 19397271 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay, IC50=5.6μM. | 17043128 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect, EC50=5.63μM. | 29407990 | ||
| MRC-5 | Function assay | Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells, IC50=5.9μM. | 10966740 | ||
| HEL | Antiviral assay | Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay, EC50=5.9μM. | 22858222 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation, EC50=5.98μM. | 23811093 | ||
| HCMV AD 169 | Antiviral assay | In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells, ID50=6μM. | 2993615 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50=6μM. | 21565516 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50=6.1μM. | 17709468 | ||
| MRC-5 | Function assay | Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells, IC50=6.3μM. | 9836613 | ||
| HEL | Antiviral assay | Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation, EC50=6.3μM. | 17518459 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=6.3μM. | 26001344 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation, EC50=6.5μM. | 27750154 | ||
| HELF | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50=6.52μM. | 30098481 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50=6.54μM. | 21565516 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50=6.6μM. | 17709468 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=6.79μM. | 28757102 | ||
| HEL | Function assay | Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR, IC50=7μM. | 7752205 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay, IC50=7.1μM. | 17043128 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50=7.1μM. | 22578783 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50=7.1μM. | 26001344 | ||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=7.3μM. | 28829913 | ||
| HFF | Antiviral assay | In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells, IC50=7.4μM. | 9057865 | ||
| HFF | Function assay | Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay, IC50=7.4μM. | 9438017 | ||
| HFF | Function assay | Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells, IC50=7.4μM. | 10882374 | ||
| HFF | Function assay | Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells, IC50=7.4μM. | 10882375 | ||
| HFF | Antiviral assay | Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells, IC50=7.4μM. | 10882370 | ||
| HFF | Antiviral assay | Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells, IC50=7.4μM. | 10882372 | ||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50=7.4μM. | 15509174 | ||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50=7.4μM. | 15509175 | ||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50=7.4μM. | 15509176 | ||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=7.4μM. | 28829913 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50=7.5μM. | 22578783 | ||
| HFF | Antiviral assay | Antiviral activity was determined by the HCMV plaque assay using HFF cells, IC50=7.7μM. | 9057866 | ||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation, EC50=7.8μM. | 26443550 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation, EC50=7.87μM. | 23811093 | ||
| CRFK | Antiviral assay | Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity, EC50=8.1μM. | 21565516 | ||
| HEL | Antiviral assay | Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after, EC50=8.2μM. | 23911854 | ||
| HFF | Function assay | In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay, IC50=8.4μM. | ChEMBL | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50=8.4μM. | 17709468 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=8.7μM. | 28682067 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50=9μM. | 19281225 | ||
| HEL | Antiviral assay | Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay, EC50=9.1μM. | 22858222 | ||
| MRC-5 | Function assay | Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells, EC50=9.4μM. | 12723951 | ||
| Vero | Antiviral assay | In vitro antiviral activity was measured against HSV-1 (F delta 305) in Vero cells, ID50=10μM. | 3009811 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2293 in HFF cells by PRA, IC50=10μM. | 17043128 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=11.43μM. | 29880251 | ||
| HELF | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50=11.75μM. | 30098481 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2311 in HFF cells by PRA, IC50=12.4μM. | 17043128 | ||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation, EC50=13.9μM. | 26443550 | ||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay, EC50=14.7μM. | 22858222 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation, EC50=14.9μM. | 27750154 | ||
| HEL | Antiviral assay | Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50=15.7μM. | 21565516 | ||
| HFF | Antiviral assay | Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay, IC50=16.4μM. | 19010684 | ||
| HEL | Antiviral assay | Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=16.5μM. | 28682067 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| Vero | Antiviral assay | Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay, EC50=19.3μM. | 19858259 | ||
| bone marrow cells | Cytotoxicity assay | Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50=30μM. | 16814545 | ||
| MRC5 | Antiviral assay | Antiviral activity against Human CMV T2287 in MRC5 cells by PRA, IC50=30.1μM. | 17043128 | ||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay, IC50=30.2μM. | 17043128 | ||
| neural precursor cells | Function assay | Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay | 17417631 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Ganciclovir是一种抗病毒药，作用于猫科动物1型疱疹病毒，无细胞试验中IC50为5.2 μM。 |
|---|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Ganciclovir由3种主要细胞酶代谢成三磷酸形式：（1）诱导的巨细胞病毒感染的细胞的脱氧鸟苷激酶; （2）鸟苷酸激酶;和（3）磷酸甘油酸激酶。[1] 在与HSV-TK表达细胞共同培养的大部分旁观者细胞中， Ganciclovir足以诱导细胞死亡。[2] Ganciclovir显著减少转化的细胞中DNA合成，而Ganciclovir对在非转化细胞的DNA合成的影响不大。Ganciclovir表现出浓度依赖性降低成熟的DNA中的伸长率。[3] 在HSVtk所转导的B16F10黑色素瘤细胞中，Ganciclovir诱导细胞周期阻滞，而不是直接的化学效应。[4]Ganciclovir轻度抑制DNA合成。Ganciclovir处理的细胞积聚在早S期并保持直到细胞死亡，这表明Ganciclovir掺入DNA模板中对细胞毒性很重要。[5]Ganciclovir诱导的凋亡是由于药物插入DNA导致复制依赖性的DNA双链断裂的形成，并在稍后的阶段产生S和G2 / M期阻滞。Ganciclovir激起的DNA不稳定性可能是Bcl-2的水平和caspase-9/-3活化水平降低的原因。[6] | |||
|---|---|---|---|---|
| 细胞实验 | 细胞系 | BV-2 cells | ||
| 浓度 | -- | |||
| 孵育时间 | 24 h | |||
| 方法 | 将总量为2 × 10<sup>4</sup>的BV-2细胞接种于96孔板，置于含10%FBS的DMEM中培养12小时、然后血清饥饿12小时，加入不同浓度的GCV进行处理，处理24小时。在处理期间的最后8小时，将1 µCi/孔的[3H]thymidine通过脉冲加入到培养基中。最后通过β plate scintillation counter检测掺入的放射性。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Growth inhibition assay | Cell viability |
|
29845211 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | 抗病毒药物ganciclovir (GCV)在实验性自身免疫性脑脊髓炎模型中抑制小神经胶质的增殖。GCV减轻神经炎症，而且并不显著抑制外周免疫反应[7]。 | |
|---|---|---|
| 动物实验 | Animal Models | C57BL/6小鼠 |
| Dosages | 100 mg/kg | |
| Administration | i.p. | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06407232 | Not yet recruiting | Cytomegalovirus Infections|Kidney Transplant Infection|Pancreas Transplant |
University of Wisconsin Madison|Merck Sharp & Dohme LLC |
May 2024 | Phase 3 |
| NCT06057194 | Not yet recruiting | Infections Cytomegalovirus |
Maimónides Biomedical Research Institute of Córdoba|MERCK SHARP & DOHME DE ESPAÑA S.A. |
October 2023 | Phase 2 |
| NCT04706507 | Recruiting | Acute Respiratory Failure |
Fred Hutchinson Cancer Center|National Heart Lung and Blood Institute (NHLBI) |
June 29 2021 | Phase 3 |
| NCT04478474 | Completed | Cytomegalovirus Infections |
New York Medical College|Merck Sharp & Dohme LLC |
September 15 2020 | -- |
| NCT03698435 | Unknown status | Cytomegalovirus Infections |
University Medical Center Groningen |
May 25 2018 | -- |
化学信息&溶解度
| 分子量 | 255.23 | 分子式 | C9H13N5O4 |
| CAS号 | 82410-32-0 | SDF | Download Ganciclovir SDF |
| Smiles | C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 50 mg/mL ( (195.9 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Ganciclovir | Ganciclovir ic50 | Ganciclovir price | Ganciclovir cost | Ganciclovir solubility dmso | Ganciclovir purchase | Ganciclovir manufacturer | Ganciclovir research buy | Ganciclovir order | Ganciclovir mouse | Ganciclovir chemical structure | Ganciclovir mw | Ganciclovir molecular weight | Ganciclovir datasheet | Ganciclovir supplier | Ganciclovir in vitro | Ganciclovir cell line | Ganciclovir concentration | Ganciclovir nmr
